- Conditions
- Leukemia, Acute Lymphoblastic Leukemia
- Interventions
- gene-modified T cells targeted
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Epstein-Barr Virus, Cytomegalovirus Infections, Adenovirus, BK Virus Infection, Immune Deficiency
- Interventions
- Rapidly generated virus specific T (R-MVST) cells
- Drug
- Lead sponsor
- Monica Bhatia
- Other
- Eligibility
- 3 Months to 26 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Relapsed and Refractory Aggressive B- and T-cell Lymphomas, Lymphoma
- Interventions
- volasertib, belinostat
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Baltimore, Maryland • Richmond, Virginia
- Conditions
- Malignant Melanoma
- Interventions
- INKT, GM-CSF
- Biological · Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Lenalidomide, Obinutuzumab, Polatuzumab Vedotin, Rituximab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 8
- States / cities
- Marietta, Georgia • Detroit, Michigan • Columbia, Missouri + 4 more
- Conditions
- WHIM, Warts, Hypogammaglobulinemia, Immunodeficiency, Myelokathexis
- Interventions
- Busulfan, Palifermin, Plerixafor, Filgrastim, Base-edited hematopoietic stem and progenitor cells
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Solid Tumor, Adult, Refractory Cancer, Recurrent Cancer, Cancer
- Interventions
- IMA202 Product, IMADetect®
- Drug · Device
- Lead sponsor
- Immatics US, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Houston, Texas
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- YM155, Rituximab
- Drug · Biological
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 6
- States / cities
- Columbus, Georgia • Maywood, Illinois • New York, New York + 3 more
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia, Leukemia, Myeloid
- Interventions
- Cytokine-Induced Memory-like Natural Killer Cells, Interleukin-2, Venetoclax
- Biological · Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Hiv
- Interventions
- CD4 CAR+CCR5 ZFN T-cells
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Bradykinesia
- Interventions
- MSCTC-0010
- Biological
- Lead sponsor
- IMAC Holdings, Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Paducah, Kentucky • Chesterfield, Missouri • Brentwood, Tennessee
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- Lymphoma
- Interventions
- Y Zevalin, In Zevalin, Rituxan, BCNU, VP -16, Ara-C, Melphalan, Stem Cell Infusion, G-CSF
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
- Interventions
- Nivolumab, (8gy x 3), Platinum Doublet
- Drug · Radiation
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • The Bronx, New York • White Plains, New York + 1 more
- Conditions
- Neuroblastoma
- Interventions
- cyclophosphamide, topotecan, hu14.18K322A, peripheral blood stem cell harvest, surgical resection, cisplatin, etoposide, doxorubicin, vincristine, busulfan, melphalan, peripheral blood stem cell transplantation, natural killer cell infusion, radiation therapy, GM-CSF, G-CSF, mesna, levetiracetam, interleukin-2, Isotretinoin, CliniMACS
- Drug · Biological · Procedure + 2 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2025
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
- Interventions
- peripheral blood lymphocyte therapy
- Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 1 Year to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Metastatic Solid Neoplasm, Lymphoma
- Interventions
- SYNB1891, Atezolizumab
- Drug
- Lead sponsor
- Synlogic
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Hackensack, New Jersey • Columbus, Ohio + 3 more
- Conditions
- Sarcoma
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Lymphoma, Acute Leukemia
- Interventions
- NiCord® (omidubicel), Cord Blood Unit
- Drug · Other
- Lead sponsor
- Gamida Cell ltd
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 21
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 16 more
- Conditions
- Leukaemia, Lymphocytic, Chronic
- Interventions
- Ofatumumab 500mg, Ofatumumab 1000mg, Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors, Hodgkin's Disease, Myelofibrosis
- Interventions
- Total Body Irradiation with Fludarabine in UCB Transplants
- Procedure
- Lead sponsor
- Duke University
- Other
- Eligibility
- 14 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Graft Versus Host Disease
- Interventions
- Visilizumab, Tacrolimus, Methotrexate, Antithymocyte globulin (ATG)
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Castrate Resistant Prostate Cancer (CRPC)
- Interventions
- BPX-101, AP1903
- Biological · Drug
- Lead sponsor
- Bellicum Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Cancer
- Interventions
- AB801, Docetaxel
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more